Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H32O2 |
Molecular Weight | 304.4669 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)C[C@H](C)[C@]34C
InChI
InChIKey=UXYRZJKIQKRJCF-TZPFWLJSSA-N
InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1
DescriptionSources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Proviron_dr_1358760414396.pdfCurator's Comment: description was created based on several sources, including, https://www.steroidal.com/steroid-profiles/proviron-mesterolone/
Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Proviron_dr_1358760414396.pdf
Curator's Comment: description was created based on several sources, including, https://www.steroidal.com/steroid-profiles/proviron-mesterolone/
Mesterolone is an androgen receptor agonist which was developed for hormone replacement therapy in males suffering from androgen deficiency and related disorders. Mesterolone is known under the name Proviron. The drug is also used by bodybuilders and athletes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10935543 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
Palliative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
Curative | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
|||
Primary | PROVIRON Approved UseReduced efficiency in middle and advanced age, Potency disturbances, Hypogonadism, Infertility. |
PubMed
Title | Date | PubMed |
---|---|---|
Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto-5alpha-steroid-17-O-beta glucuronides and 5alpha-steroid-3alpha,17beta-diol 3- and 17-glucuronides. | 2001 Sep |
|
The role of the biochemistry department in the diagnosis of pituitary apoplexy. | 2004 Mar |
|
Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency. | 2005 |
|
Molecular cloning and characterization of a nuclear androgen receptor activated by 11-ketotestosterone. | 2005 Aug 17 |
|
Nonsurgical treatment of male infertility: specific and empiric therapy. | 2007 Sep |
|
Microbial oxidation of anabolic steroids. | 2008 |
|
Hepatocyte nuclear phenotype: the cross-talk between anabolic androgenic steroids and exercise in transgenic mice. | 2008 Nov |
|
Adverse effect of the anabolic-androgenic steroid mesterolone on cardiac remodelling and lipoprotein profile is attenuated by aerobicz exercise training. | 2008 Oct |
|
Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. | 2009 Jul 7 |
|
Morphological changes in murine skeletal muscle in response to exercise and mesterolone. | 2010 |
|
Effect of high intensity aerobic exercise and mesterolone on remodeling of Achilles tendon of C57BL/6 transgenic mice. | 2010 Feb |
Patents
Sample Use Guides
The tablets should be swallowed whole with some liquid. The recommended doses are: 1 tablet (25 mg) 3 times/day (reduced efficiency and potency disturbances), 1 tablet 2-3 times/day (Infertility), 1-2 tablets 3 times/day (for development of secondary male sex characteristics in hypogonadism).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10935543
Mesterolone showed activation effect on mutant androgen receptor (expressed in HeLa and COS-7 cells) at doses 0.1–300 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
4000
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Mesterolone
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
||
|
WHO-VATC |
QG03BB01
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
||
|
WHO-ATC |
G03BB01
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
75054
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
3342
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
C87227
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
215-836-3
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
100000091044
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
6781
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | RxNorm | ||
|
1424-00-6
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
DTXSID90878533
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
15020
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
0SRQ75X9I9
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
D008655
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
SUB08790MIG
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
MESTEROLONE
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
1965
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL258918
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
DB13587
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | |||
|
m7256
Created by
admin on Sat Dec 16 15:57:32 GMT 2023 , Edited by admin on Sat Dec 16 15:57:32 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY